SUMMARY Anti-cartilage antibodies, demonstrable by immunofluorescence, were found in 3-3 % of rheumatoid arthritis patients. In most of these patients antibodies to type II collagen were detected. In specificity studies on these anti-collagen antibodies, they appeared to be type specific, showing no reaction with collagen types I and III. Denatured type II collagen reacted much less well than native type II, but isolated peptides from different regions of the collagen molecule were differentiated by individual sera. Removal of the glycoside side chains from native type II collagen had no effect on its antigenicity. The findings suggest that these patients produce highly specific antibodies which react with the triple helix of type II collagen.
Collagen fibres are major constituents of all connective tissues where they provide mechanical strength. The fibres are built up ofcollagen molecules, which, in native form, have three polypeptide chains aligned in a rigid, rod-shaped structure with a triple helical conformation.' In the last decade, more than fivedifferent types of collagen have been identified,2-5 which differ in their chemical composition, their tissue distribution, and their biological properties.6 7 Type II collagen has a particularly limited tissue distribution, occurring only in cartilage, intervertebral disc, and notochord.2 8 9 The potential importance of collagen in connective tissue diseases, such as rheumatoid arthritis, has been pointed out more than once.10 11 It has been suggested that collagen may behave as an autoantigen in human patients," and, recently, a rat model of arthritis has been developed in which native type II collagen was shown to induce pathological changes in the joints. Other collagen types or denatured collagen did not have this capacity.12 A recent publication in this journal described the occurrence of anti-cartilage antibodies in patients with rheumatoid arthritis.13 These antibodies appeared in 3-3% of 1126 rheumatoid arthritis patients but were absent in 1825 blood donors and in patients with osteoarthrosis, ankylosing spondylosis, polymyalgia rheumatica, or gout. Antibodies to type II collagen were detected in most patients with Received for publication 31 March 1980 anti-cartilage antibodies. In this paper additional studies on the specificity of these anti-collagen antibodies are described.
Material and methods

SOURCE OF SERA
All sera originated from patients with definite rheumatoid arthritis, as previously described. ' A number of these sera were also reacted with native type II collagen in a solid phase fluorimetric assay. Five sera (AA, BW, FC, KK, SA) gave very weak reactions in agreement with their haemagglutination titres (10, < 5, 20, 5, < 5, respectively) whereas two sera which were variable by haemagglutination (FH and HJ-see previous section) showed evidence of IgG binding in this assay. IgG binding to collagen was almost always higher than IgM binding (Figure) , suggesting that the antibodie3 were predominantly IgG class. Table 2 , denatured type II collagen reacted with these antibodies in all cases, but much less strongly than the native collagen. 
REACTION WITH ISOLATED COLLAGEN PEPTIDES
The above findings indicated that the antigenic determinants were, to some degree, dependent on the native triple helical structure of collagen, this conformation being lost on heat denaturation.
However, it appears that the structure of denatured collagen is sufficiently similar to native for it to retain a slight degree of antigenicity. Collagen peptides isolated from different regions of chick type II collagen following cyanogen bromide digestion were available from previous work.15 Preparations contained CB8, CB10, or CB1 1, the large peptides from the centre of the collagen chain, and mixtures of CB9 + 12 and CB6 + 7, smaller peptides located near the carboxy and amino terminals. Since these peptides originated from different regions of the type II molecule and had different primary structures, it was decided to test their reactivity with anti-collagen antibodies.
Six sera were first tested for their ability to cross-react with denatured chick type II collagen. Three sera reacted poorly, and three reacted equally well with chick or human collagen. A similar heterogeneity was found among patients' sera when examined by immunofluorescence using rat and chick laryngeal cartilage. The latter three sera were then reacted with isolated chick type II peptides in haemagglutination inhibition, as shown in Table 3 . Two of these sera were able to distinguish individual peptides, while the third reacted well with all the peptides tested.
REACTION WITH PERIODATE-TREATED COLLAGEN
Type II collagen contains glycoside side chains attached O-glycosidically to hydroxylysine. It is possible to remove these groups by oxidation, so that their importance to collagen antigenicity can be assessed.
In this study, glycoside side chains were removed by periodate treatment, which was shown to reduce the glucose content of collagen from 05 % w/w to less than 0.1 % w/w. This treatment had little effect on the ability of collagen to inhibit the haemagglutination reaction for five different human sera (Table 4) . It would appear, therefore, that the sugar residues were irrelevant to antigenicity in these cases. 
Discussion
We have demonstrated the presence of antibodies to type II collagen in most of the rheumatoid sera which showed anti-cartilage staining by immunofluorescence. Specificity studies on randomly selected sera showed that the anti-collagen antibodies were all specific for type II collagen and did not react with types I or III. All sera tested showed specificity for the native helical structure of collagen and reacted poorly with denatured collagen in which this conformation was lost as a result of gentle heating. It seemed possible that antibodies in these rheumatoid sera may have reacted, not with native collagen itself, but with some other molecule which attached to collagen and formed an antigenic hapten. Such a hapten could link to collagen through the sugar residues. However, this idea was discounted in our study since removal of the sugar residues of collagen by periodate oxidation had no effect on its antigenicity.
Although all the sera tested showed consistent reactions with native or periodate-treated collagen, individual variations were observed in their reactions with chick cartilage (immunofluorescence), chick type II collagen, and its isolated cyanogen bromide peptides. Individual peptides reacted differently with three sera tested. Although this gives no information on the location of the antigenic determinants, which are clearly associated with the triple helix, it does indicate that these three sera had differing specificities. Similar subtle variations have been found among anti-collagen antisera raised in rabbits. 18 The antibodies occurred in 3.3 % of 1126 rheumatoid arthritis patients.13 14 Other workers have found a similar incidence among small groups of patients, for example, 2/47 with anti-collagen'9 and 1/35 with anti-cartilage antibody.20 There have, however, been many reports of a much higher incidence of antibodies to collagen in rheumatoid arthritis patients. 1"192122 In some cases nonantibody proteins, such as fibronectin,'4 may have bound to denatured collagen, giving falsely positive results. When a high incidence of antibodies to native collagen has been found,19 2123 all sera have reacted with more than one type of collagen. Since it has been shown that IgG bound native collagen through its Fc region,24 and human collagenase reacted with native collagen in haemagglutination,25 it is possible that some of these reactions may have been non-specific. In any case these type non-specific reactions are clearly distinct from the antibodies to native type II collagen which we have described.
There are no clinical means of distinguishing patients with anti-collagen antibodies from those without, although the incidence of antibodies is higher in patients with articular erosions. There is also an association with disease activity in so far as antibodies occur significantly more often in patients with a raised C-reactive protein (unpublished data).
The findings described here do not help in determining the role of anti-cartilage antibody, but it is interesting to speculate on why rheumatoid arthritis should give rise to an antibody directed at the intact molecule rather than at its breakdown products, a finding contrary to what might be expected of an antibody produced secondarily to tissue damage. The explanation may lie in a greater antigenicity of the native molecule in certain individuals. Experimental work in animals has shown that guinea-pigs, rats, and mice produce antibodies to native but not denatured collagen, whereas chicken and rabbits recognised both forms of collagen.'5 26 There were a few anti-cartilage sera in which we could not demonstrate antibodies to collagen either by haemagglutination or by solid phase fluorimetry. There is thus a possibility that some at least of our sera contained antibodies to cartilage components other than collagen.
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